Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival

Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute.

Read the whole article on Physorg

More from Physorg